Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLuis Alberto Diaz, Benoit Rousseau, Neil H. Segal
Estimating the term…
In some embodiments the present invention provides methods useful for the treatment of MMR-proficient and/or microsatellite stable (MSS) cancers and also useful for enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, and/or increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells. In some embodiments such methods involve administration of a combination of temozolomide and cisplatin, or a combination of temozolomide, cisplatin and an immune checkpoint inhibitor, to a subject in need thereof.
A method of treating an MMR-proficient and/or microsatellite-stable colorectal cancer in a subject in need thereof, the method comprising:
A method of treating an MMR-proficient and/or microsatellite-stable cancer in a subject in need thereof, the method comprising:
The method of any of the preceding claims wherein the method enhances the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject.
The method of any of the preceding claims wherein the method enhances the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject to immune checkpoint blockade.
The method of any of the preceding claims wherein the method induces an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject.
The method of any of the preceding claims wherein the method increases the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject.
A method of enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, the method comprising contacting the cancer cells with an effective amount of an imidazotetrazine chemotherapeutic agent and a platinum-containing chemotherapeutic agent.
A method of enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, the method comprising contacting the cancer cells with an effective amount of an imidazotetrazine chemotherapeutic agent and a platinum-containing chemotherapeutic agent.
A method of inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, the method comprising contacting the cancer cells with an effective amount of temozolomide and a platinum-containing chemotherapeutic agent.
A method of increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells, the method comprising contacting the cancer cells with an effective amount of an imidazotetrazine chemotherapeutic agent and a platinum-containing chemotherapeutic agent.
A pharmaceutical composition comprising:
A pharmaceutical composition comprising:
A pharmaceutical composition comprising:
A pharmaceutical composition comprising:
A pharmaceutical composition comprising:
A pharmaceutical composition comprising:
A combination comprising:
A combination comprising:
A combination comprising:
A combination comprising:
A combination comprising:
A combination comprising:
Dependencies are inferred from the claim text.